Korsana Biosciences, Inc. (KRSA) income statement
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30508% above fair value
$33.27+0.77 (+2.37%)
Close on Nov 18, 2026Market cap $155.75MP/E –Yield –
Korsana Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -359.2%
- Net margin
- -353.0%
- Return on equity, FY2025
- -39.3%
Financial strength
- Current ratio
- 0.82
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 75.5%
Valuation
- P/E ratio
- –
- Price to sales
- 81.97
- Price to book
- 30.62
- Dividend yield
- –
See a number that looks wrong?